Clinical Trials Browser

Interventional × selinexor × Gynecologic × Clear all

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

NCT05611931 2026-02-02

XPORT-EC-042

Phase 3 Recruiting

276 enrolled

Gynecologic

Endometrial Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04811196 2025-05-29

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

Phase 1 Completed

56 enrolled

GynecologicSarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Neurofibrosarcoma

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Phase 2 Recruiting

40 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT02025985 2023-01-26

SIGN

Phase 2 Completed

116 enrolled 21 charts

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02269293 2021-04-23

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Phase 1 Completed

23 enrolled

Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

Clinical Trials

ENGOT-EN5

XPORT-EC-042

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

SIGN

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers